Research and Development Expense. Research and development expense was RMB1.7 million ($0.3 million), demonstrating the Company's continued commitment to enhancing operating efficiency through technological improvements.
Sales and Marketing Expense. Sales and marketing expense increased 5.7% to RMB13.3 million ($2.0 million) from RMB12.6 million in the prior year period, as a result of continuous marketing and promotional activities in Beijing Municipality and Guangdong Province. Sales and marketing expense accounted for 14.0% of revenue.
General and Administrative Expense. General and administrative expenses were RMB23.3 million ($3.6 million), compared to RMB12.4 million in the prior year period. General and administrative expenses as a percentage of revenue was 24.6%, compared to 17.5% during the prior year period.
NET INCOME ATTRIBUTABLE TO SHAREHOLDERS. Net income attributable to shareholders for the fourth quarter of fiscal 2011 rose 62.8% to RMB26.3 million ($4.0 million) from RMB16.1 million for the prior year period. Net margin for the fourth quarter of fiscal 2011 rose to a new record of 27.7% from 22.8% in the fourth quarter of fiscal 2010. Basic earnings per share in the fourth quarter of fiscal 2011 were RMB0.35 ($0.05).
LIQUIDITY. As of March 31, 2011, the Company had cash and cash equivalents of RMB611.4 million ($93.4 million), compared to RMB280.8 million as of March 31, 2010. The Company had total debt of RMB45.0 million ($6.9 million) as of March 31, 2011.
"As we established our solid presence in Beijing and Guangdong, we successfully developed a reputable and quality brand," Ms. Zheng stated. "In order to capture even greater future growth, we have ch
|SOURCE China Cord Blood Corporation|
Copyright©2010 PR Newswire.
All rights reserved